Taysha Gene Therapies is a pre-revenue clinical-stage gene therapy company with a single dominant asset: TSHA-102 for Rett syndrome, an intrathecal AAV9 therapy targeting MECP2 loss-of-function. The Q1 2026 earnings call on 2026-05-06 materially de-risked the BLA approval path on three independent variables simultaneously. The next path-step compression event is approximately three weeks away.

What the call said

CEO Sean Nolan stated, unprompted, that the FDA 6-month interim BLA submission path is confirmed in writing following a BTD Type B meeting: "It's in writing, by the way. It's as good as you can get." Three filing scenarios were articulated — full approval at 6 months, rolling review with completion at 12 months, or full 12-month data. This converts the BLA timing from a relationship-dependent variable to a documented optionality during CBER leadership turnover (Marks gone, Prasad departing end of April 2026).

CFO Kamran Alam: "CMC is not on the critical path to a potential BLA submission." PPQ campaign initiated April 2026 at Catalent Baltimore. FDA endorsed the comparability strategy in a Q1 2026 Type C meeting. Multiple lots already proven comparable.

President Sukumar Nagendran on enrollment: "We are over-enrolled, and we have more than enough patients to dose to meet the 15." Zero screen failures in Part A. Dosing completing Q2 2026 for both REVEAL Part B (pivotal) and ASPIRE (ages 2-4 safety extension). Zero treatment-related SAEs/DLTs across all three trials as of May 2026 cutoff.

Cash $276.6M, runway "into 2028." Q1 burn $42.4M front-loaded with PPQ manufacturing.

What the market thinks

TSHA diluted market cap roughly $240-300M post the +33.8% 1-month run. With $276.6M cash, EV is approximately $0-30M. Backed against a $1.5B fair-value-on-approval target and $150-200M cashbox floor, the market is pricing P(approval) ≈ 5-12%.

Options confirm a bullish but partially priced setup: 63-day ATM IV at 126.6%, call OI 482× puts, ATM straddle implies ±30.6% move over 63 days — the market is pricing the Part A 12mo press release as a ≈30% event, but not pricing the conditional path-risk compression that follows each subsequent step.

Why the gap exists

The worldview joint P(approval) is approximately 34% on path-conditional math, lifting to 50-55% conditional on Part A 12-month durability. Edge versus market: 22-29 percentage points on terminal probability.

Five reasons the gap persists:

1. Pre-revenue biotech reflexive haircut
2. Gene therapy CMC CRL base rate (74% of CGT CRLs cite manufacturing)
3. Elevidys-class AAV safety overhang (3 ALF deaths; IV delivery, mechanistically distinct from TSHA's IT route)
4. CBER leadership uncertainty
5. Single-source manufacturing (no backup CDMO; CFO punted on redundancy)

The call materially de-risked items 2 and 4. The market has not yet repriced for the program-specific nature of the FDA written commitment, confirmed by cross-ticker corroboration: NGNE's 10-Q filed 2026-05-12 reaffirms its primary endpoint at MONTH 12, while TSHA holds a documented 6-month option.

Risks ranked by impact

1. Part A 12-month any patient loss of previously-gained milestone — kills BLA path, exit trigger
2. Catalent Baltimore Form 483 escalation or warning letter — revives manufacturing critical path
3. Single-source manufacturing tail at pre-approval inspection — un-addressed; SRRK added two fill-finish facilities pre-resubmission as best practice
4. NGNE successfully negotiates 6-month endpoint revision under its BTD — compresses TSHA timing-lead thesis
5. CBER permanent director appointment skeptical of accelerated CGT approval — partially hedged by written commitments

Catalysts

• ≈3 weeks (late May / early June 2026): Part A 12-month press release, all 12 patients. Press release format, not conference. Largest single near-term LR event.
• End Q2 2026: REVEAL Part B + ASPIRE dosing completion
• Q4 2026: PPQ completion; 6-month pivotal interim readout
• Q1 2027: BLA filing target
• 2028: PDUFA / approval decision

What would change our mind

Any single Part A patient losing a previously-gained milestone (management has stated this has never occurred); a Catalent Baltimore warning letter or escalating Form 483; insider Form 4 S cluster from C-suite; NGNE 8-K disclosing FDA agreement for 6-month interim endpoint revision; equity raise materially above $75M before BLA filing (would imply burn higher than guided or timeline slipping).

A paired structure (TSHA versus NGNE at ≈1:0.4-0.5 notional) isolates idiosyncratic variance above 90%, neutralizing XBI/CBER/AAV class beta while capturing the cross-ticker corroborated relative-value gap; NGNE's 29.8% short interest provides natural funding. An outright position carries ≈25-35% factor beta in exchange for absolute approval optionality.

Evidence